Drug Search Results
More Filters [+]

TRV120027

Alternative Names: trv120027
Latest Update: 2023-07-18
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: AT1 Inhibitor

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Trevena
Company Location: CHESTERBROOK PA 19087
Company CEO: Carrie L. Bourdow
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for TRV120027

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Heart Failure

Phase 1: Kidney Diseases|Heart Failure

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CP120027.1002

P1

Completed

Heart Failure|Kidney Diseases

2012-05-01

2010-020376-37

P2

Completed

Heart Failure

2012-04-06

CP120027.2001

P2

Completed

Heart Failure

2012-03-01

Recent News Events